Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 64%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is poised for success as a promising player in the oncology market due to its strong sales and potential FDA approvals for their portfolio of new products that target various mechanisms of action in cancer treatment. With a focused pipeline and a solid financial standing, the company is receiving positive ratings from analysts and shows potential for long-term value creation and growth.

Bears say

BeOne Medicines is a holding company with a negative outlook due to its narrow focus on oncology treatments and dependence on a single product, BRUKINSA, for the majority of its revenue. The recent positive results and guidance raise are positive indicators, but the potential near-term approvals of sonrotoclax and BGB-16673 for r/r MCL and CLL, respectively, are not yet guaranteed and have not been factored into revenue estimates. Additionally, the company's solid tumor pipeline is still in early stages, and with the deprioritization of several early-stage programs, BeOne Medicines may face challenges in diversifying its portfolio.

BeiGene Ltd (ONC) has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 64% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 11 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $387.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $387.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.